Progress Your Project With Our DMPK Services
At Sygnature Discovery we have built a DMPK drug discovery team with a wealth of experience. This enables us to do more than just deliver accurate data: we provide expert analysis and interpretation of the results. This is a key feature in helping drive your project forward.
We offer an extensive range of validated in silico, in vitro and in vivo DMPK services for drug discovery, backed up by a comprehensive portfolio of analytical techniques. We can design flexible DMPK screening cascades to support medicinal chemistry programmes, including bespoke method development.
DMPK Drug Discovery Services
Working closely with Chemistry and Bioscience, our approach is one of collaboration, partnering with clients to develop a greater understanding of the target and the properties that a successful drug should have. Expert guidance and problem-solving suggestions from our experienced team will help you optimise potential drug molecules, increasing the likelihood of success.
Our experts specialise in seven key areas:
DMPK Consultancy
We offer a range of DMPK consultancy services to drug discovery research teams within the academic, pharmaceutical, biotechnology, charity and CRO sectors as well as to life science venture capital funds.
In Silico and PBPK Modelling
Our In Silico Modelling uses the GastroPlusTM software package that simulates absorption, distribution, metabolism and elimination in humans and animals from a range of dose routes including oral, intravenous, inhaled, ocular and dermal.
In Vivo Pharmacokinetics (PK)
We offer services to support your non-GLP in vivo Pharmacokinetics studies in preclinical species including the planning of these studies and the analysis of any samples generated by UPLC-MS.
Metabolite Drug Identification (Met-ID)
Our DMPK and biotransformational capabilities are supplemented by extensive expertise in complementary analytical techniques, including high-resolution mass spectrometry, nuclear magnetic resonance, chemically intelligent software algorithms and mass spectrometry imaging.
Physicochemical Properties of Drugs
It is well understood that poor physicochemical properties are associated with increased failure of drug candidates within the pre-clinical and clinical development process. Assessing these parameters during the discovery optimisation process is critical.
In Vitro ADME Pharmacology
The assessment of the Absorption, Distribution, Metabolism, and Excretion (ADME) properties of compounds is a critical component is supporting the development of compounds within Discovery and Development.
Bioanalysis
Our non-GLP bioanalysis service brings together the latest instrumentation and technology which is used to provide quantitative measures of metabolites for pharmacokinetics, toxicokinetics, bioequivalence and exposure-response studies.
Delivering for our customers - a proven track record
- 48 pre-clinical candidates delivered
- 27 already progressed to clinical trials (>50%)
- Sygnature Discovery co-inventors named on >170 client patent applications
-1.png?width=862&height=596&name=Performance%20graph%20only%20(with%20atom%20filigrane)-1.png)